INFORMATION DISCLOSURE

STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10698215
	Filing Date		2003-10-31
First Named Inventor John			A. Baumann
	Art Unit		3723
Examiner Name Robi			ert C. Watson
	Attorney Docket Numb	er	BO1-0116US

		Remove				
Examiner Cite Patent Number Kind Code ¹ Is		Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	2052380		1936-08-25	Chapman	
	2	3712529		1973-01-23	Ozawa et al.	
	3	4492015		1985-01-08	Dearman	
	4	4582241		1986-04-15	Johnson	
	5	5172846		1992-12-22	Hayashi et al.	
	6	5263632		1993-11-23	Zadnick et al.	
	7	5535938		1996-07-16	Leduc	
	8	6127646		2000-10-03	Aebersold et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

6189764

B1 2001-02-20

Application Number		10698215
Filing Date		2003-10-31
First Named Inventor John		A. Baumann
Art Unit		3723
Examiner Name Robe		ert C. Watson
Attorney Docket Number		BO1-0116US

	10	6371353	B1	2002-0	4-16	lkeda et al.					
	11	6666371	B2	2003-1	2-23	Nakazawa et al.					
	12	6722556	B2	2004-0	4-20	Schilling et al.					
If you wisl	h to a	dd additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicat of cited Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear		e vant	
	1	20050093219	A1	2005-0	5-05	Baumann					
If you wisl	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d button	Add		
				FOREIG	SN PAT	TENT DOCUM	ENTS		Remove		
		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	or	vhere Re	or Relevant	76			
	1	FR2576371	FR			1985-07-16	SOLLMANN OTTO	(DK)			
	2	GB1332523	UK			1971-01-07	AERONCA INC				
					_						

	3	GB2169836	uĸ	A	1986-07-23	SOLLMANN OTTO ALOIS		
If you wisi	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add buttor	Add	
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Cite No							
	1							
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add							
	EXAMINER SIGNATURE							

See Not Code of USPTO Peter Documents at sew USETO COLV or MPEP 901.04. * Enter of this that issued the document, by the bro-later code (NPPO Solandar 513.) **Ever planese peter for comment, the children's or the year of the right of the Emperor many precess the send number of the plant for the Internal precess the send number of the plant for the Internal precess the send number of the plant for the Internal precess the send number of the plant for the Internal precess the send number of the plant for the Internal Precess that is not the Internal Precess that is not to the Internal Precess that is not the Internal Precess that In

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10698215	
Filing Date		2003-10-31	
First Named Inventor John		A. Baumann	
Art Unit		3723	
Examiner Name Robo		rt C. Watson	
Attorney Docket Number		BO1-0116US	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
П	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
_	information disclosure statement. See 37 CFR 1 97(e)(1)

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(40).

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

□ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Frank J. Bozzo, Reg No. 36756/	Date (YYYY-MM-DD)	2006-06-08
Name/Print	Frank J. Bozzo	Registration Number	36756

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolffice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via yet of sicklosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via filed in application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.